secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-06-10T11:40:43+00:00
Accession:  0001437749-26-020080
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed raises $10.5M in private placement; shifts focus to strategic partnering for neflamapimod in DLB
--------------------------------------------------------------------------------

- Gross proceeds ~$10.5M from sale of 3.36M units at $3.14 each; up to $21.7M additional if warrants fully exercised.
- Insiders including chair Joshua Boger, CEO John Alam trusts, and director Sylvie Grégoire purchased ~1.37M units.
- Net proceeds extend cash runway into Q2 2027; funds neflamapimod R&D and general corporate purposes.
- Strategic priority to find a partner for Phase 3 in dementia with Lewy bodies after FDA/EMA alignment on registration path.
- Near-term milestones: nfvPPA Phase 2a clinical data Q1 2027; ALS Phase 2a trial initiation Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926020080/0001437749-26-020080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926020080/crvo20260610_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-020080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer